Status:
RECRUITING
The Effect of Chimeric Antigen Receptor (CAR)-T Cell Therapy on the Reconstitution of HIV-specific Immune Function
Lead Sponsor:
Guangzhou 8th People's Hospital
Collaborating Sponsors:
Sun Yat-sen University
Conditions:
HIV/AIDS
Eligibility:
All Genders
18-60 years
Phase:
PHASE1
Brief Summary
To study the safety and effectiveness of CAR-T Cell therapy on HIV patients whose plasma HIV has been successfully suppressed after cART, which is expected to enhance the res-constitution of HIV-speci...
Detailed Description
Despite the advent of combined antiretroviral therapy (cART), the persistence of viral reservoirs remains a major barrier to curing human immunodeficiency virus type 1 (HIV-1) infection. Recently, the...
Eligibility Criteria
Inclusion
- HIV infection confirmed.
- Receiving cART more than 12 months.
- HIV viral-load \< 50 copies/ml and CD4 cell count more than 350 cells/ul.
- Without serious liver, heart, liver and kidney diseases.
- The subjects know about the study and volunteer to attend the research and sign the informed consent.
Exclusion
- With active HBV or HCV infection, or serious opportunistic infections.
- With serious chronic disease such like diabetes, the mental illness,et al
- History of suffering from pancreatitis during cART.
- Pregnant or breast-fed.
- With poor adherence.
- Unable to complete follow up.
Key Trial Info
Start Date :
October 4 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2030
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT03240328
Start Date
October 4 2017
End Date
December 31 2030
Last Update
September 14 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Guangzhou 8th People's Hospital
Guangzhou, Guangdong, China, 510060